UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 24, 2012

 

 

LVB ACQUISITION, INC.

BIOMET, INC.

(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

 

 

 

Delaware

Indiana

 

000-54505

001-15601

 

26-0499682

35-1418342

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

56 East Bell Drive

Warsaw, Indiana 46582

(Address of Principal Executive Offices, Including Zip Code)

(574) 267-6639

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 8.01.     Other Events.

On May 24, 2012, DePuy Orthopaedics, Inc. (“DePuy”) accepted Biomet’s binding offer to acquire DePuy’s worldwide trauma business following completion of DePuy’s consultation obligations with various European works councils and has executed the asset purchase agreement dated as of April 2, 2012 that was included as part of the binding offer. The binding offer was made in order to permit DePuy to comply with its consultation obligations with various European works councils prior to entering into a negotiated, mutually binding purchase agreement. The transaction remains subject to receipt of regulatory approvals and other customary closing conditions. Biomet is a wholly owned subsidiary of LVB Acquisition, Inc. (“LVB”). LVB has no other operations beyond its ownership of Biomet.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 25, 2012

 

LVB ACQUISITION, INC.
/s/ Daniel P. Florin
By:   Daniel P. Florin
Its:   Senior Vice President and Chief Financial Officer

 

BIOMET, INC.
/s/ Daniel P. Florin
By:   Daniel P. Florin
Its:   Senior Vice President and Chief Financial Officer